<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0370-3908</journal-id>
<journal-title><![CDATA[Revista de la Academia Colombiana de Ciencias Exactas, Físicas y Naturales]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. acad. colomb. cienc. exact. fis. nat.]]></abbrev-journal-title>
<issn>0370-3908</issn>
<publisher>
<publisher-name><![CDATA[Academia Colombiana de Ciencias Exactas, Físicas y Naturales]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0370-39082018000300166</article-id>
<article-id pub-id-type="doi">10.18257/raccefyn.558</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio preliminar de anticuerpos IgG antiinsulínicos y complejos inmunitarios en pacientes colombianos con diabetes tipo 2]]></article-title>
<article-title xml:lang="en"><![CDATA[Preliminary study of anti-insuline IgG antibodies and immune complexes in Colombian patients with type 2 diabetes]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Romero]]></surname>
<given-names><![CDATA[Yohana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santa]]></surname>
<given-names><![CDATA[Jorge Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bohórquez Villamizar]]></surname>
<given-names><![CDATA[Luisa Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado Murcia]]></surname>
<given-names><![CDATA[Lucy Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia Departamento de Farmacia Grupo de Investigación en Inmunotoxicología]]></institution>
<addr-line><![CDATA[Bogotá D.C.]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Bogotá D.C.]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2018</year>
</pub-date>
<volume>42</volume>
<numero>164</numero>
<fpage>166</fpage>
<lpage>179</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0370-39082018000300166&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0370-39082018000300166&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0370-39082018000300166&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El uso terapéutico de insulina exógena de origen animal para el tratamiento de la diabetes mellitus se ha asociado con la inducción de anticuerpos antiinsulínicos, los cuales alterarían la seguridad y la eficacia de esta formulación. Con la introducción de la tecnología del ADN recombinante y la producción de insulinas con secuencias similares a la humana, se redujo, pero no se eliminó, la aparición de dichos anticuerpos. En el marco del análisis de la inmunogenicidad inducida por las proteínas terapéuticas y con el objetivo de evaluar el perfil de inmunidad humoral de tres formulaciones comerciales de insulina exógena humana (insulina regular, insulina Neutral protamine Hagedorn [NPH], e insulina glargina), se estudió la presencia de anticuerpos antiinsulínicos en 29 muestras de suero de pacientes con diabetes tipo 2, y se caracterizó su reactividad cruzada, su perfil según la subclase de IgG y su capacidad para formar complejos inmunitarios. Los pacientes se clasificaron en tres grupos según su tratamiento: a) insulina regular y NPH (n=10), b) insulina NPH (n=9) y c) glargina (n=10). La detección, caracterización y evaluación de las subclases de IgG se hizo mediante ELISA indirecto, y la detección de complejos inmunitarios constituidos por anticuerpos antiinsulínicos e insulina exógena, mediante ELISA de captura. Los resultados permitieron evidenciar que: i) cada formulación de insulina es reconocida de manera diferencial por los anticuerpos antiinsulínicos, lo cual sugiere un mayor potencial inmunogénico de la insulina NPH y uno menor de la insulina glargina; ii) el perfil según la subclase de IgG de los anticuerpos antiinsulínicos en humanos es diferencial para cada formulación, siendo predominante la subclase IgG3 para la insulina NPH en pacientes en tratamiento con insulina regular y NPH; iii) la presencia de anticuerpos antiinsulínicos no se asoció con alteraciones de los parámetros metabólicos analizados, y iv) los complejos inmunitarios constituidos por anticuerpos antiinsulínicos e insulina exógena no se detectaron con la metodología utilizada en los sueros de los pacientes con diabetes tipo 2 estudiados. Los resultados obtenidos permiten concluir que existen diferencias entre el perfil inmunogénico de las insulinas evaluadas, lo cual es importante en el análisis de la inmunogenicidad de dichas formulaciones en cuanto a su seguridad y eficacia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The therapeutic use of exogenous insulin of animal origin for the treatment of diabetes mellitus has been associated with the development of insulin antibodies, which raises concerns regarding the safety and efficacy of this formulation. With the advent of recombinant DNA technology and the generation of insulin with human-like sequences, the production of insulin antibodies has been reduced but not eliminated. As part of the analysis of immunogenicity induced by therapeutic proteins and to evaluate the immunogenic profile of three commercial formulations of human exogenous insulin (regular, neutral protamine Hagedorn (NPH), and glargine) we evaluated the presence of insulin antibodies in 29 serum samples from volunteers with type 2 diabetes, and we characterized their cross-reactivity, IgG subclass profile, and ability to form immune complexes. To this end, volunteers were classified into three groups according to their current insulin therapy: a) Regular and NPH insulin (n=10); b) NPH (n=9), and c) glargine (n=10). For the detection, characterization, and evaluation of the IgG subclasses we used an indirect ELISA test, and for the detection of immune complexes formed by insulin antibodies and exogenous insulin, capture ELISA. Our results evidenced that: i) Each insulin formulation was recognized differentially by the insulin antibodies suggesting a greater immunogenic potential for NPH insulin and a lower one for glargine insulin; ii) the IgG subclasses profile of insulin antibodies in humans was different for each formulation; the IgG3 subclass for NPH insulin was predominant in volunteers treated with regular and NPH insulin; iii) the presence of insulin antibodies was not associated with alterations in the metabolic parameters analyzed, and iv) immune complexes composed of exogenous insulin antibodies were not detected in the sera of diabetic volunteers. The results obtained in this study allowed us to conclude that there are differences between the immunogenic profile of the insulin formulations tested, which has significant value in the analysis of their immunogenicity with regard to their safety and efficacy.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[anticuerpos insulínicos]]></kwd>
<kwd lng="es"><![CDATA[insulina exógena]]></kwd>
<kwd lng="es"><![CDATA[complejo inmune]]></kwd>
<kwd lng="es"><![CDATA[diabetes]]></kwd>
<kwd lng="es"><![CDATA[ELISA.]]></kwd>
<kwd lng="en"><![CDATA[Insulin antibodies]]></kwd>
<kwd lng="en"><![CDATA[exogenous insulin]]></kwd>
<kwd lng="en"><![CDATA[immune complexes]]></kwd>
<kwd lng="en"><![CDATA[diabetes]]></kwd>
<kwd lng="en"><![CDATA[ELISA.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association (ADA)</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care in Diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<numero>^sSupplement 1</numero>
<issue>^sSupplement 1</issue>
<supplement>Supplement 1</supplement>
<page-range>S14-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<collab>Asociación Latinoamericana de Diabetes (ALAD)</collab>
<source><![CDATA[Guías ALAD de diagnóstico control y tratamiento de la diabetes mellitus tipo 2]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[O. O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of anti-insulinantibodies]]></article-title>
<source><![CDATA[Acta Endocrinologica]]></source>
<year>1976</year>
<volume>205</volume>
<page-range>231-40</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berson]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Yalow]]></surname>
<given-names><![CDATA[R. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bauman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rothschild]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Newerly]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects]]></article-title>
<source><![CDATA[The Journal of Clinical Investigation]]></source>
<year>1956</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>170-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J.-W.]]></given-names>
</name>
<name>
<surname><![CDATA[Frystyk]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lauritzen]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Christiansen]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes]]></article-title>
<source><![CDATA[European Journal of Endocrinology]]></source>
<year>2005</year>
<volume>153</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>907-13</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Comisión de regulación en salud</collab>
<source><![CDATA[Actualización de Plan Obligatorio de Salud]]></source>
<year>2011</year>
<page-range>115</page-range><publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devey]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Aspects of IgG Subclasses and Therapeutic Implications]]></article-title>
<source><![CDATA[Immunology]]></source>
<year>1988</year>
<volume>65</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>327</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Mario]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Ventriglia]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Iavicoli]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Guy]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Andreani]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The correlation between insulin antibodies and circulating immune complexes in diabetics with and without microangiopathy]]></article-title>
<source><![CDATA[Clinical And Experimental Immunology]]></source>
<year>1983</year>
<volume>52</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>575-80</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dib]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Freire]]></surname>
<given-names><![CDATA[M. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[W. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[E. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of insulin antibodies by radioassay and ELISA: interrelation and correlation with metabolic control in type I diabetes]]></article-title>
<source><![CDATA[Brazilian Journal of Medical and Biological Research]]></source>
<year>1994</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1167-80</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Inmunodetección de anticuerpos antiinsulina libres en suero Y unidos a la molécula de insulina en pacientes insulino-dependientes]]></source>
<year>2014</year>
<page-range>46-8</page-range><publisher-name><![CDATA[Universidad Nacional de Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eyzaguirre]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Codner]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin analogues: searching for a physiological replacement]]></article-title>
<source><![CDATA[Revista Medica de Chile]]></source>
<year>2006</year>
<volume>134</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>239-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fineberg]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Kawabata]]></surname>
<given-names><![CDATA[T. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Finco-Kent]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Fountaine]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Finch]]></surname>
<given-names><![CDATA[G. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Krasner]]></surname>
<given-names><![CDATA[A. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological responses to exogenous insulin]]></article-title>
<source><![CDATA[Endocrine Reviews]]></source>
<year>2007</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>625-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[A. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hanning]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[K. G. M. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>1985</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>330-4</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hattori]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Shimatsu]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with insulin glargine causes anti-insulin antibody production more frequently than other insulin analogs in patients with diabetes mellitus]]></article-title>
<source><![CDATA[Endocrine Reviews]]></source>
<year>2013</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heding]]></surname>
<given-names><![CDATA[L. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[M. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Persson]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlquist]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Thalme]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Lindgren]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaad]]></surname>
<given-names><![CDATA[P. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity of monocomponent human and porcine insulin in newly diagnosed Type 1 (insulin-dependent) diabetic children]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>1984</year>
<volume>27</volume>
<page-range>96-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spatial structure of immunoglobulin molecules]]></article-title>
<source><![CDATA[Klinische Wochenschrift]]></source>
<year>1980</year>
<volume>58</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1217-31</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<collab>International Diabetes Federation</collab>
<source><![CDATA[IDF Diabetes Atlas 2017]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Irvine]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Di Mario]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Guy]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Iavicoli]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pozzilli]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lumbroso]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Andreani]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune complexes and diabetic microangiopathy]]></article-title>
<source><![CDATA[Journal of Clinical &amp; Laboratory Immunology]]></source>
<year>1978</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>187-91</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishizuka]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Nako]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamichi]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Oka]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies]]></article-title>
<source><![CDATA[Diabetes Research and Clinical Practice]]></source>
<year>2009</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>21e-3e</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Itoh]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Saisho]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsuishi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Oikawa]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Kawai]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody - A case report]]></article-title>
<source><![CDATA[Diabetes Research and Clinical Practice]]></source>
<year>2011</year>
<volume>94</volume>
<page-range>e53-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jefferis]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumararatne]]></surname>
<given-names><![CDATA[D. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective IgG subclass deficiency: quantification and clinical relevance]]></article-title>
<source><![CDATA[Clinical and Experimental Immunology]]></source>
<year>1990</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>357-67</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[François-Gérard]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Sodoyez-Goffauxl]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Sodoyez]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semi-quantitative assessment of antiinsulin total IgG and IgG sub-classes in insulin-immunized patients using a highly sensitive immunochemical micromethod]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>1986</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>720-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koyama]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakanishi]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashita]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwahara]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Katori]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: Treatment with double filtration plasmapheresis and prednisolone]]></article-title>
<source><![CDATA[American Journal of the Medical Sciences]]></source>
<year>2005</year>
<volume>329</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>259-64</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lahtela]]></surname>
<given-names><![CDATA[J. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Knip]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Antonen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Salmi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe antibody-mediated human insulin resistance: Successful treatment with the insulin analog lispro: A case report]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1997</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-3</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nyhan]]></surname>
<given-names><![CDATA[D. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Shampaine]]></surname>
<given-names><![CDATA[E. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hirshman]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[R. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[S. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Baumgartner]]></surname>
<given-names><![CDATA[W. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Adkinson]]></surname>
<given-names><![CDATA[N. F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single doses of intravenous protamine result in the formation of protamine-specific IgE and IgG antibodies]]></article-title>
<source><![CDATA[Journal of Allergy and Clinical Immunology]]></source>
<year>1996</year>
<volume>97</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>991-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Técnicas inmunoenzimáticas para ensayos clínicos de vacunas y estudios inmunoepidemiológicos]]></source>
<year>2012</year>
<page-range>14</page-range><publisher-loc><![CDATA[La habanaI ]]></publisher-loc>
<publisher-name><![CDATA[Finlay Ediciones]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pieber]]></surname>
<given-names><![CDATA[T. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Eugène-Jolchine]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Derobert]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2000</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>157-62</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ratanji]]></surname>
<given-names><![CDATA[K. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Derrick]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Dearman]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kimber]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity of therapeutic proteins: Influence of aggregation]]></article-title>
<source><![CDATA[Journal of Immunotoxicology]]></source>
<year>2014</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-109</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reeves]]></surname>
<given-names><![CDATA[W. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin antibodies induced by bovine insulin therapy]]></article-title>
<source><![CDATA[Clinical and Experimental Immunology]]></source>
<year>1982</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>163-70</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schernthaner]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Borkenstein]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Fink]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mayr]]></surname>
<given-names><![CDATA[W. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Menzel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schober]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1983</year>
<volume>6</volume>
<numero>^sSuppl. 1</numero>
<issue>^sSuppl. 1</issue>
<supplement>Suppl. 1</supplement>
<page-range>43-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segal]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Viner]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Pusey]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Wild]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Allgrove]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe insulin resistance secondary to insulin antibodies: Successful treatment with the immunosuppressant MMF]]></article-title>
<source><![CDATA[Pediatric Diabetes]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>250-4</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sodoyez-Goffaux]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dozio]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Brandenburg]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Sodoyez]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assays of insulin antibodies]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>1988</year>
<volume>31</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>694-702</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Deshazo]]></surname>
<given-names><![CDATA[R.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Mather]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Frentz]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Lauritano]]></surname>
<given-names><![CDATA[A.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Total IgG and IgG subclass specific antibody responses to insulin in diabetic patients]]></article-title>
<source><![CDATA[Annals of Allergy]]></source>
<year>1991</year>
<volume>67</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>499-503</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thalange]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Bereket]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[L. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Hiort]]></surname>
<given-names><![CDATA[L. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Peterkova]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of Insulin Detemir/ Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2--16 Years]]></article-title>
<source><![CDATA[Diabetes Therapy]]></source>
<year>2016</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>713-24</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urbaniak]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[MA]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. III. Comparison of IgG anti-D agglutinating and lytic (ADCC) activity and the role of IgG subclasses]]></article-title>
<source><![CDATA[British Journal of Haematology]]></source>
<year>1980</year>
<volume>46</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>447-53</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vajo]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Fawcett]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Duckworth]]></surname>
<given-names><![CDATA[W. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant DNA technology in the treatment of diabetes: Insulin analogs]]></article-title>
<source><![CDATA[Endocrine Reviews]]></source>
<year>2001</year>
<volume>22</volume>
<page-range>706-17</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valla]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps]]></article-title>
<source><![CDATA[Experimental Diabetes Research]]></source>
<year>2010</year>
<volume>2010</volume>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[M. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Nyhan]]></surname>
<given-names><![CDATA[D. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[Z. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Horrow]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lowenstein]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Hirshman]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine]]></article-title>
<source><![CDATA[Anesthesia and Analgesia]]></source>
<year>1989</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>3-5</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yanai]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Adachi]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Hamasaki]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: Successful treatmentwith the newest insulin analog glulisine]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>108-e108</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[T. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Xiong]]></surname>
<given-names><![CDATA[Z. Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequent reoccurrence of hypoglycemia in a type 2 diabetic patient with insulin antibodies]]></article-title>
<source><![CDATA[Molecular Diagnosis and Therapy]]></source>
<year>2010</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>237-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
